BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces a collaboration agreement with one of the world leading vaccine companies to develop a vaccine application of its Lauriad® mucoadhesive technology. The terms of this agreement are not disclosed at this time.
This research program aims at establishing the feasibility of using Lauriad® technology for vaccination, leading to an efficient needle-free administration based on the application to the gum of this mucoadhesive tablet containing a vaccine antigen. Moreover, this would also avoid the constraints related to manufacturing sterile injectable forms.
This project is carried out within the Fluriad™ consortium set in March 2011, co-labeled by both “Clusters of excellence” Medicen Paris Region and Atlanpôle Biotherapies and financed up to €2 million by the “Fond Unique Interministériel” (a French program supporting collaborative research projects).
“This collaboration with one of the world leading vaccine companies shows the potential interest of our innovative Lauriad® system for a needle-free vaccination. This is also a major step taken to increase the value of our proprietary Lauriad® technology, already validated through three major products of our portfolio: Loramyc® and Sitavig®, already registered, and Validive®, in phase II clinical development”, stated Judith Greciet, CEO of BioAlliance Pharma. “A first successful feasibility would open the way to promising new opportunities in vaccine field with significant market potential worldwide”.